Business Context and Reporting Period
This Form 8-K is a current report filed by OncoGenex Pharmaceuticals, Inc. (noted as "ACHIEVE LIFE SCIENCES, INC." in metadata, but identified as OncoGenex in the filing text) on August 4, 2011. The report serves to announce the Company's financial results for the second quarter of 2011 via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The filing text provided is a cover sheet and does not contain specific numerical data. It references a press release (Exhibit 99.1) for details on revenue, profit, cash flow, margins, debt, and liquidity. Consequently, the filing text does not provide a clear value for any specific financial metric.
Material Changes
No material changes versus the prior comparable period are detailed in the text of this Form 8-K. The document solely indicates that results for the second quarter of 2011 have been issued.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies within the provided text. It explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the press release dated August 4, 2011), as they are not included in this summary text.
- Confirm the company name discrepancy: The metadata lists "ACHIEVE LIFE SCIENCES, INC." while the filing text identifies the registrant as "ONCOGENEX PHARMACEUTICALS, INC."
- Note that the financial data in the referenced press release is not legally "filed" under Section 18 of the Exchange Act per the disclaimer in this document.